Stromal fibroblast senescence has been linked to ageing-associated cancer risk. However, density and proliferation of cancer-associated fibroblasts (CAFs) are frequently increased. Loss or downmodulation of the Notch effector CSL (also known as RBP-Jκ) in dermal fibroblasts is sufficient for CAF activation and ensuing keratinocyte-derived tumours. We report that CSL silencing induces senescence of primary fibroblasts from dermis, oral mucosa, breast and lung. CSL functions in these cells as a direct repressor of multiple senescence-and CAF-effector genes. It also physically interacts with p53, repressing its activity. CSL is downmodulated in stromal fibroblasts of premalignant skin actinic keratosis lesions and squamous cell carcinomas, whereas p53 expression and function are downmodulated only in the latter, with paracrine FGF signalling as the probable culprit. Concomitant loss of CSL and p53 overcomes fibroblast senescence, enhances expression of CAF effectors and promotes stromal and cancer cell expansion. The findings support a CAF activation-stromal co-evolution model under convergent CSL-p53 control.
Most genetic hallmarks of epithelial cancer are already present in premalignant in situ lesions, which rarely progress into fullblown cancers [1] [2] [3] . Cellular senescence provides an intrinsic failsafe mechanism against tumour development 4 . However, senescence of stromal fibroblasts is associated with production of growth factors, cytokines, extracellular matrix components and degrading enzymes (senescence message secretome) that promote tumour development 5, 6 . As such, stromal cell senescence has been implicated in increased incidence of many cancer types with age 5, 7 . However, increased density and proliferation of cancer-associated fibroblasts (CAFs), rather than senescence, are frequently observed around tumours 8, 9 . Senescent cells can be cleared by mechanisms such as macrophage activation 10 , and there can be selective pressure for stromal fibroblasts with CAF properties to escape senescence 1, 8, 9, [11] [12] [13] [14] .
Increased determinants of cellular senescence such as p53/ p21 WAF1/Cip1 or p16 Ink4a do not induce senescence message secretome production 15 , and mechanisms linking fibroblast senescence with CAF activation are not known. Information on transcriptional events leading from normal fibroblasts to established CAFs is also scant. CSL is a DNA-binding protein with intrinsic transcription repressive function converted into a transcriptional activator by activated Notch 16 . Mice with mesenchymal CSL gene deletion develop a skin field cancerization phenotype, with dermal fibroblast alterations preceding inflammatory infiltrates and, by 2-4 months, multifocal keratinocyte tumours 17 . We report here that CSL functions as a direct repressor of both senescence-and CAF-determinant genes in stromal fibroblasts from various organs, with CSL-p53 interactions functioning as a failsafe mechanism against cancer stromal cell evolution and expansion.
RESULTS

CSL as a common repressor of fibroblast senescence and CAF activation
Newborn mice with mesenchymal CSL gene deletion exhibit signs of atrophic and/or ageing skin, with reduced dermal thickness and altered extracellular matrix 17 . Staining of skin sections for senescenceassociated β-galactosidase (SA-β-Gal) activity showed widespread positivity of dermal cells ( Fig. 1a and Supplementary Fig. 1a ), which was enhanced in stroma of premalignant lesions in older mice ( Fig. 1b and Supplementary Fig. 1b ). Importantly for the later studies, the Supplementary Fig. 1b ).
(c) Immunofluorescence of parallel sections for phospho-histone 3 (p-H3), vimentin and F4/80 and quantification of p-H3-positive fibroblasts (vimentin positive, F4/80 negative); from left to right: n(cells) = 367, 603, 298, 453, 284 and 493, assessed from three, four, three, four, three and four fields, respectively; mean ± s.d., two-tailed paired t-test. (d,e) SA-β-Gal staining (d) and clonogenicity assays (e) of second passage dermal fibroblasts from mice plus/minus CSL deletion with corresponding quantification. (d) n(cells) = 323 (WT) and 135 (KO), assessed from four and seven fields respectively; (e) n = 3 biological replicates/condition. (f,g) SA-β-Gal (f) and clonogenicity (g) assays of HDFs plus/minus CSL silencing. (f) Left to right, n(cells) = 118, 72 and 111 assessed in four, six and six fields, respectively; (g) n = 3 biological replicates per condition. Similar results were obtained with two other strains ( Supplementary Fig. 2b,c) . (h,i) Independent HDF strains plus/minus CSL silencing by shRNA (h) and siRNA (i) analysed by RT-qPCR: (h) n(HDF strains) = 8 CSL shRNA 1 + 2, 4 control shRNA; (i) n(HDF strains) = 8 CSL siRNA 1 + 2, 4 control siRNA. (j) HDFs plus/minus CSL silencing analysed by immunoblotting. One blot probed for p53, p21 WAF1/Cip1 , CSL, γ-tubulin; another for IL-6, β-actin; and another for p16 Ink4a , γ-tubulin. Similar p21 induction was observed in two other independent experiments ( Fig. 7c,d) , with p21 and IL-6 immunofluorescence ( Supplementary Fig. 2h ) as confirmation. For unprocessed blots see Supplementary Fig. 9 . (k) SA-β-Gal assays of fibroblasts from oral mucosa (HOF), breast (HBF), lung (HLF and WI-38) plus/minus CSL silencing; from left to right n(cells) = 207, 251, 274, 201, 206, 200, 223, 203, 200, 276, 222 and 249, assessed from 4, 11, 11, 5, 8, 7, 3, 7, 10, 4, 7 and 4 fields, respectively. (l) Cells as in k were analysed by RT-qPCR; n(fibroblast types) = 4 control shRNA, 8 CSL shRNA 1 + 2. (d-g,k) Mean ± s.d., two-tailed unpaired t-test; (h,i,l) ratio log 2 (CSL/control), two-tailed one-sample t-test. * P < 0.05. Unprocessed original scans of blots/gels are shown in Supplementary Fig. 9 . -Immune response-complement pathway (Factor H, C3b, C3dg, C3a, C3, C3c, iC3b; I-kB, ICAM1, CCL2, GCP2) -DNA replication and metabolism (RFC5, GINS1, CLSPN, DNA2, CDC45, BLM, POLE2, MCM10, RAD54L, HMGA1,SOD2, BARD1) -Apoptosis (TRAF2, IFIH1, CCL2, ZMAT3, APH1B, NFKBIA, MST4, HMOX1, MX1,  FOSL1, HELLS, ANGPTL4, IRAK1,KLF10, BIRC3, SOD2, TNFRSF10A Figure 2 CSL expression and function in CAFs. (a) Immunoblotting of CAFs from several skin SCCs soon after culturing (p2) and on expansion (p4; * ) in parallel with several HDF strains. The blot was probed for CSL, α-SMA and γ-tubulin with densitometric quantification; n(strains) = 5 HDF, 4 CAF, 5 CAF * , mean ± s.e.m., two-tailed unpaired t-test. Similar results were obtained in a second independent experiment (right panel). (b) Same CAF strains as in a, transduced with lentiviral vector for doxycycline-inducible Myc-tagged CSL or pIND vector control were analysed by immunoblotting. (c) CAFs as in b were analysed by RT-qPCR for the indicated genes; n(CAF strains) = 3 pIND control, 3 pIND-CSL, two-tailed one-sample t-test. (d) DsRed2-expressing SCC13 cells admixed with CAFs (strain no. 2) plus/minus constitutive lentiviral CSL expression were injected in parallel into ears of three NOD/SCID Il2rg −/− 10-week-old male mice. Representative images and signal quantification relative to day 1; d.p.i., days post injection. n = 3 per condition, mean ± s.e.m., two-tailed paired t-test at day 10. (e) Immunofluorescence for proliferation (phospho-histone 3, p-H3) and epithelial (pankeratin) markers. (f) CSL levels in published gene expression profiles of CAFs from skin SCCs (from general populations (cSCC) and from patients with recessive dystrophic epidermolysis bullosa (RDEB-SCC)); head/neck SCC, breast cancer and lung cancer; skin, n = 5 SCC, 4 RDEB-SCC, 3 healthy individuals; head and neck, n = 7 SCC, 5 healthy individuals; breast, n = 23 carcinoma, 5 healthy individuals; lung, n = 4 NSCLC, 15 healthy individuals; two-class comparison with moderated tstatistic. Median, upper and lower quartiles are represented. Vertical whiskers indicate variability outside the upper and lower quartiles. (g) Heat maps of differentially expressed genes in HDFs plus/minus CSL silencing relative to data sets of CAFs from skin and head/neck SCCs. Genes modulated by CSL silencing in HDFs (>1.4-fold) concordantly or discordantly down-or upregulated in clinically occurring CAFs are indicated by dark and light turquoise and magenta colours, respectively. Selected pathways or processes with a statistically significant enrichment (P < 0.05) are indicated along with representative genes. A complete list is provided in Supplementary Table 1 . PTGS2  SERPINA9  LDHA  SERPINA11  HPSE2  SERPINA12  HAS2  LOXL2  C3  PLOD2  OAS1  MMP2  SERPINA3  MMP9  SERPINA4  MMP13  SERPINA5  MMP16   Enzymes/MMPs   Membrane  bound/surface  expressed   ITGA3  ITGB6  TGFBR2  PDGFRa  FLT4  IL1R2  FZD10  TNFRSF6B  TNFRSF10C  THY1  CD96  KAL1   AP-1   JUNB  FOSL1  FOSL2   POSTN  LAMA1   COL3A1  LAMB3  ELN  LAMB4  FBN1  LAMC2  SPARC  LAMC3  DCN  TNC  VCAN  FGA  APOD   ECM   VEGFB  IGFBP4  PTHLH  VEGFC  GDF6  CXCL12  TGFA  PDGFB  CCL3  TGFB2  PDGFC  CCL7  FGF7  WNT1  CXCL8  FGF9  WNT2  IL17A  FGF10  WNT3  IL-7  FGF18  WNT9A  IL-1B  FGFBP1  SFRP1  IL-2  FGFBP2  NREP  IL-12A  SPRY1  NODAL  IL32  EGF  NDNF  TNFSF13B  IGF1  BMP2  SLPI  IGFBP2  SEMA3E Growth factors/hormones/cytokines COL1A2 LAMA3
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CSL Ab CS CSL Ab HM Input Figure 3 CSL as a direct negative regulator of senescence-and CAF-effector genes. (a) Top: maps of the predicted CSL-binding sites (positions indicated in blue) relative to the TSS and mapped within the proximal enhancers and promoter regions of the indicated genomic loci (grey and black boxes, respectively; obtained from ENCODE). Each map is at a different scale, as indicated by bars. Bottom: ChIP assays with two different antibodies against CSL (HM, home made; CS, Cell Signaling; grey and black bars, respectively) were carried out in parallel with non-immune IgG controls for the indicated chromosomal sites (numbers) containing predicted CSL recognition sequences. Independent ChIP assays with two other HDF strains are shown in Supplementary Fig. 3f . (b) List of CAF-related and AP-1 family members that were found to be targeted by CSL by ChIP-Seq analysis with two different antibodies against CSL. A more detailed list of genes with specific localization of CSL-binding peaks is provided in Supplementary Table 2 .
(c) Graphic illustration of the position of CSL-binding peaks revealed by ChIP-Seq analysis with two different antibodies (red and blue colours) for the indicated genes, utilizing ENCODE information for promoter and enhancer localization, as indicated by islands of histone H3 modifications (K4m3 and K27Ac, respectively), along with the respective position of the TSS (arrow) and coding exons (black boxes). For JUNB, the entire locus, as delimited by binding peaks of the CTCF insulator, is shown. Results for two further loci (MMP13 and FOSL2) are shown in Supplementary Fig. 3g .
fraction of proliferating fibroblasts was also enhanced at this stage ( Fig. 1c and Supplementary Fig. 1c ). Dermal fibroblasts from mice plus/minus CSL deletion had initially similar attachment and proliferation rates when cultured. However, at the first and, more markedly, second passages, mutant fibroblasts exhibited senescence-associated morphology, increased SA-β-Gal activity and reduced clonogenicity ( Fig. 1d,e ). Similar consequences were caused by short hairpin RNA (shRNA)-mediated silencing of CSL in primary human dermal fibroblasts (HDFs) from individuals of different genders and ages ( Fig. 1f,g and Supplementary Fig. 2a -c), in parallel with overall reduction of cell proliferation ( Supplementary Fig. 2d,e ). Downmodulation of CSL by either shRNA or short interfering RNA (siRNA) silencing induced expression of senescence determinants such as CDKN2B (p15 INK4b ), CDKN2A (p16 INK4a ), CDKN1A (p21 WAF1/Cip1 ) and miR-34a, in parallel with senescence message secretome and CAF marker genes ( Fig. 1h-j and Supplementary Fig. 2f -h). Similar effects were elicited by CSL silencing in primary fibroblasts from oral mucosa, breast and lung ( Fig. 1k,l and Supplementary Fig. 2i ,j).
Notch receptor activation converts CSL from a repressor into an activator of transcription 16 . Similarly to CSL silencing, inducible expression of activated Notch1 induced cellular senescence-and CAF-effector genes ( Supplementary Fig. 3a-d ). Endogenous Notch activation through jagged 1 ligand exposure led to similar outcomes ( Supplementary Fig. 3e ).
Relative to several HDF strains, freshly derived CAFs from various skin squamous cell carcinomas (SCCs) exhibited, together with elevated alpha smooth muscle actin marker (α-SMA) expression, low CSL levels ( Fig. 2a ). Exogenously increased CSL in these cells caused suppression of CAF marker genes, mirroring CSL silencing effects in HDFs (Fig. 2b,c) . Findings were further validated in vivo, utilizing an overexpression were incubated with biotinylated oligonucleotide with tandem CSL and p53 binding sites of the CDKN1A gene (WT) or oligonucleotide with site disruption (mt). Pulldown samples were immunoblotted with antibodies against CSL and p53 (turquoise and magenta, respectively). Lower panels: Fluorescence signal quantification. (g) p53 luciferase reporter activity in HDFs co-transfected with two siRNAs against CSL (pooling siRNA samples for the assay) versus scrambled controls. Shown are composite results of two independent experiments; n = 4 biological replicates, mean ± s.d., two-tailed paired t-test. * P < 0.05. (h) p53 luciferase reporter activity in 293T cells plus/minus co-transfection of p53 and CSL-expressing plasmid in increasing amounts. Similar results were obtained in three other independent experiments. (i) p300 immunoprecipitation from 293T cells co-transfected with p53 and CSL-expressing plasmid in increasing amounts followed by immunoblotting for p53, p300 and CSL. Similar results were obtained in two other independent experiments as shown in Supplementary  Fig. 4d . (b-d,f,i) Unprocessed original scans of blots are shown in Supplementary Fig. 9 . 
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Ratio log 10 (lesion/normal) Ratio log 10 Only a minority of cells double stained for vimentin and CD68 macrophage marker ( Supplementary Fig. 5e ). n(vimentin-positive cells in P1-5) = 345, 397, 310, 183, 111 (NS) and 345, 397, 310, 183, 111 (AK); mean signal intensity as individual data points; two-tailed paired t-test. (c) LCM of AKunderlying stroma versus flanking normal stroma (NS) and RT-qPCR analysis; n = 5 AKs and 5 flanking regions; mean of ratio log 10 (AK/NS) ± s.e.m. The significance of differences in CSL expression was calculated using a twotailed one-sample t-test ( * P < 0.0001), and that of the inverse relation between CSL and CDKN1A or IL-6 expression using the Pearson coefficient (−0.92 and −0.88, respectively; * P < 0.05). (d) LCM-obtained PDGFRαpositive cells ( Supplementary Fig. 5j ) from stroma underlying (n = 5) and flanking (n = 5) in situ SCC lesions and unaffected stroma (n = 6) from other individuals (face and abdomen derived, black and grey circles) were analysed by RT-qPCR for indicated genes; mean ± s.e.m., two-tailed unpaired t-test, * P < 0.05. (e) LCM-obtained stroma from invasive SCC (n = 5) and normal skin (NS, n = 5) samples from different individuals were analysed by RT-qPCR for the indicated genes; mean ±s.e.m., twotailed unpaired t-test, * P < 0.05. (f) LCM-obtained stroma from skin SCCs (two lesion areas, A, B) and matching surgically discarded normal skin from three patients were analysed by RT-qPCR; n = 6 SCC and 3 normal regions, one-sample t-test, * P < 0.005). (g) LCM-obtained stroma from skin lesions (two lesion areas, A, B) of 3-month-old mice with mesenchymal CSL deletion (the same as in Fig. 1b,c and Supplementary Fig. 1b ,c) and matching stroma of unaffected skin were analysed by RT-qPCR for the indicated genes; n = 5 affected and 3 unaffected regions, one-sample t-test, * P < 0.005. ear injection-tumour imaging assay described later. Outgrowths of fluorescently labelled skin SCC-derived cells (SCC13) expanded much less when admixed with CAFs with increased CSL versus controls, with corresponding differences in cancer cell proliferation ( Fig. 2d,e ).
In gene expression profiles of CAFs from skin 18 , head/neck 19 , breast 20 and lung 21 cancers, relative to normal fibroblasts from the same body sites, expression of CSL was consistently downmodulated (Fig. 2f ). Published expression profiles of CAFs from skin and head/neck SCCs (refs 18,19) were compared with those of HDFs plus/minus CSL gene silencing obtained by RNA sequencing (RNA-Seq) analysis. 56% of differentially modulated genes in HDFs with CSL silencing were similarly regulated in the published CAF profiles, whereas 44% of genes were discordantly regulated ( Fig. 2g and Supplementary Table 1 ). Functional classification showed differential distribution of affected pathways (Metacore) and processes (Gene Ontology). Development-related genes such as CSL and jagged 1 were commonly downregulated, together with genes involved in migration and somitogenesis. Commonly upregulated were genes impinging on activator protein 1 (AP-1)-dependent transcription, extracellular matrix remodelling and smooth muscle cell proliferation 
Modulation of p53 gene transcription and activity in dermal fibroblasts and CAFs as function of FGFR signalling. (a) Immunoblot analysis of p53 expression in CAFs from several skin SCCs soon after culturing (passage 2) and on expansion (passage 4; * ) in parallel with a set of HDF strains under similar growth and passage conditions. The p53 blot was reprobed with antibodies against α-SMA (left panel). Results were quantified by densitometric scanning after signal normalization for the housekeeping protein (right panel); n(strains) = 5 HDF, 4 CAF, 5 CAF*, mean ± s.e.m., two-tailed unpaired t-test. (b) Early passage HDFs were treated with the indicated growth factors/cytokines (at the concentrations specified in methods), followed 72 h later by RT-qPCR analysis of p53 expression. Results of a similar experiment with a second HDF strain of different origin are shown in Supplementary Fig. 6a . (c) The same cells as in b were treated with the indicated growth factors followed by immunoblot analysis of p53 expression. (d) Early passage HDFs were treated with a multitarget tyrosine kinase inhibitor with potent anti-FGFR activity (ponatinib) or a more FGFR-selective inhibitor (BGJ398) versus one devoid of such activity (imatinib), followed 72 h later by analysis of p53, CDKN1A and miR-34a expression by RT-qPCR. Similar results were obtained with a second independent strain ( Supplementary Fig. 6b ).
(e) HDFs treated as in the previous panel were analysed for levels of p53 expression by immunoblotting, with similar results with a second HDF strain, shown in Supplementary Fig. 6c . (f) Two independent CAF strains were treated with ponatinib at the indicated concentrations for 72 h followed by immunoblot analysis of p53 expression. (g) Similar CAF cultures treated as in f were analysed for CDKN1A and miR-34a levels using RT-qPCR. (a,c,e,f) Unprocessed original scans of blots are shown in Supplementary Fig. 9 .
and function, consistent with our other results and previous work 17 . Other development-related genes, including Wnt signalling components (Fzd, Wnt2 and DKK1) and fibroblast growth factor receptor 2 (FGFR2), were upregulated in CAFs and downmodulated in HDFs with CSL silencing. Interestingly, genes downmodulated in CAFs and upregulated in HDFs with silenced CSL had distinct functions, ranging through immune regulation, DNA replication, metabolism and apoptosis ( Fig. 2g ). Many apoptosis-related genes, such as MX1, HMOX1, IFIH1, CCL2, SERPINB2 and IL12A, are also implicated in senescence and some are p53 targets (for example CCL2) [22] [23] [24] , consistent with our further findings on escape from p53 in established CAFs.
Senescence-and CAF-determinant genes as direct CSL targets
We hypothesized that CSL functions as a direct repressor of senescence-and CAF-determinant genes. Bioinformatics analysis Figure 7 Escape from senescence and enhanced CAF marker expression in stromal fibroblasts with concomitant CSL and p53 gene silencing. (a) HDFs were infected with control versus p53 silencing retroviruses, followed by infection with either control or CSL silencing lentiviruses. The number of cells positive for SA-β-Gal activity was determined a week later (left). The same cells were also plated under sparse conditions, followed by determination of colony formation 10 days later (right). For SA-β -Gal activity n = 131 (control shRNA + control shRNA), 127 (CSL1 shRNA + control shRNA), 130 (CSL2 shRNA + control shRNA), 314 (p53 shRNA + control shRNA), 151 (p53 shRNA + CSL1 shRNA), 184 (p53 shRNA + CSL2 shRNA) cells assessed from four fields for each condition, except for CSL1 shRNA + control shRNA and CSL2 shRNA + control shRNA from six and eight fields, respectively; for clonogenicity assay n = 3 biological replicates/condition. Results of a similar experiment with an independent strain of HDFs are shown in Supplementary Fig. 7b . (b) HDFs plus/minus CRISPR-mediated disruption of the p53 gene (obtained and characterized as shown in Supplementary Fig. 7a ) were infected with control versus CSL silencing lentiviruses, followed by determination of SA-β-Gal activity and colony forming ability. For SA-β-Gal activity n = 159 (p53-WT + control shRNA), 126 (p53-WT + CSL1 shRNA), 201 (p53-WT + CSL2 shRNA), 164 (p53 CRISPR + control shRNA), 186 (p53 CRISPR + CSL1 shRNA), 207 (p53 CRISPR + CSL2 shRNA) cells assessed from five fields for each condition, except for p53-WT + CSL1 shRNA and p53-WT + CSL2 shRNA assessed from seven fields; for clonogenicity assay n = 3 biological replicates/condition. (c) The same strain of HDFs as in a was transfected with siRNAs against CSL plus/minus siRNAs for p53, followed, 3 days later, by a repeat transfection. Cell extracts were analysed 3 days later by immunoblotting against the indicated proteins. (d) HDFs with CRISPRmediated p53 gene disruption were transfected, in parallel with control parental cells, with siRNAs against CSL followed by immunoblot analysis of the indicated proteins. (e,f) HDFs plus/minus CSL and p53 gene silencing as in a were analysed by RT-qPCR for expression of the indicated genes. Results of a similar experiment with an independent strain of HDFs are shown in Supplementary Fig. 7c . (a,b) Mean ± s.d., two-tailed unpaired t-test; * P < 0.05. (c,d) Unprocessed original scans of blots are shown in Supplementary Fig. 9 .
revealed putative CSL-binding sites in enhancer and/or promoter regions of multiple senescence-effector genes such as CDKN1A, CDKN2A, miR-34a and IL6. Chromatin immunoprecipitation (ChIP) assays of HDFs with two different antibodies against CSL showed binding of this protein to two sites in the CDKN1A locus, at −9.7 kilobases (kb) and −2.3 kb from the transcription start site (TSS) ( Fig. 3a and Supplementary Fig. 3f ). Many predicted CSL-binding sites are present in the large miR-34a locus. Among six tested sites, CSL was found to bind to one, at 14 kb from the TSS ( Fig. 3a and Supplementary Fig. 3f ). CSL binding was also detected at one enhancer of the CDKN2A gene and several enhancers and the promoter region of the IL6 gene ( Fig. 3a ).
Many genes have been implicated as CAF effectors or markers 8, 9, 25, 26 . We assessed whether any are CSL targets by ChIP-Seq (ChIP combined with massively parallel DNA sequencing) analysis of HDFs, utilizing the same two antibodies against CSL as for ChIP assays (Supplementary Table 2 ). Out of 139 CAF-related genes identified from literature searches, 77 exhibited overlapping binding peaks with the two antibodies, with statistically significant enrichment (P = 2.46495 × 10 20 ) relative to the total fraction of genes with CSLbinding peaks at the genome-wide level (5, 190 out of 26,019, mapped with the ChIPpeakAnno package from Bioconductor) ( Fig. 3b and Supplementary Table 2 ). CSL binding to at least 40 CAF-related genes is of probable functional significance, as their expression was differentially modulated in HDFs plus/minus CSL silencing (P = 1.26751 × 10 15 ) (Supplementary Table 2 ). Identified CSL targets extended to all categories of CAF-related genes, including those with pro-inflammatory and/or growth modulatory functions, matrix composition/remodelling and surface markers. Genes for several AP-1 family members, inducers of CAF markers under negative Notch/CSL control 17 , were also direct CSL targets ( Fig. 3b and Supplementary Table 2 ). In some genes (tenascin C and JunB), CSL binding was proximal or downstream of the TSS, whereas in others (PTGS2, also known as COX-2; MMP13 and FOSL2), CSL binding occurred at upstream distant enhancers ( Fig. 3c and Supplementary  Fig. 3g and Supplementary Table 2 ).
CSL-p53 functional and physical interactions
The two CSL-binding sites in the CDKN1A locus have closely adjoining p53 recognition sequences (sites no. 3 and no. 5), pointing to possibly close interactions between the two proteins. ChIP assays of HDFs showed binding of p53 only to the −2.3 kb site, which was consistently enhanced on CSL silencing (Fig. 4a ). p53 binding to another target, MDM2, was affected by CSL silencing to a lesser extent (Fig. 4a) , whereas binding to BAX, related to apoptosis 27 , remained undetectable. Supplementary Fig. 8b . (e) Diagrammatic illustration of the process leading from normal fibroblasts to CAFs with CSL and p53 as critical determinants, as proposed in the discussion.
CSL may affect p53 activity through physical interaction. Endogenous p53 and CSL association could be readily detected by coimmunoprecipitation experiments with HDFs under basal conditions and with induced p53 expression ( Fig. 4b and Supplementary   Fig. 4a,b ). Association of p53 with CSL was confirmed by overexpression of epitope-tagged proteins (Fig. 4c ). When the two purified recombinant proteins were incubated with each other, followed by coimmunoprecipitation, effective association was also detected (Fig. 4d ).
Microscale thermophoresis (MST; ref. 28 ) confirmed direct CSL-p53 binding, with affinity between 113 nM and 120 nM ( Fig. 4e and Supplementary Fig. 4c ).
Cell extract pulldown assays were carried out with an oligonucleotide with the CSL and p53 binding sites of the CDKN1A gene and a control with single nucleotide changes disrupting CSL and p53 recognition. The two proteins were effectively pulled down by the specific oligonucleotide, and binding of one protein was unaffected by overexpression of the other (Fig. 4f ). To assess p53 transcriptional activity, cells were transfected with a p53 luciferase reporter. Basal p53 activity was increased in HDFs by silencing of CSL (Fig. 4g) . Conversely, p53-induced activity was decreased by exogenous CSL expression, in dose-dependent fashion (Fig. 4h) . The p300 co-activator plays a central role in p53-dependent transcription 29 . Co-immunoprecipitation analysis showed that association of endogenous p53 and p300 was suppressed by increasing amounts of CSL, paralleling dose-dependent suppression of p53 activity ( Fig. 4i and Supplementary Fig. 4d ).
Downmodulation of p53 expression and function in CAF activation
An important question is whether control of fibroblast senescence and CAF activation can be genetically dissociated. Consistent with this possibility, SA-β-Gal staining of clinically occurring premalignant keratinocytic lesions (actinic keratoses; AKs) revealed senescent stromal cells in various proportions with non-senescent cells, depending on individual patients and lesion areas ( Fig. 5a and Supplementary Fig. 5a ). Scattered stromal cell senescence was also found around in situ SCCs, whereas there was little or none in invasive SCCs, in which increased fibroblast density was frequently observed ( Fig. 5a and Supplementary Fig. 5a-d) .
Immunofluorescence and laser capture microdissection (LCM) followed by quantitative PCR with reverse transcription (RT-qPCR) analysis of AK stromal tissues showed downmodulation of CSL expression and upregulation of CDKN1A and IL-6 relative to stroma of surrounding normal skin, whereas levels of p53 were unaffected (Fig. 5b,c and Supplementary Fig. 5e ).
In situ skin SCCs are characterized by pronounced cellular atypia extending to all epidermal layers, without, as yet, cell invasion. Relative to less advanced AK lesions, more widespread stromal alterations around these lesions are likely to occur, as part of expanding cancer fields. In fact, LCM analysis of stromal fibroblasts underlying these lesions, as well as flanking skin, showed that CSL levels were consistently reduced relative to an external set of age-and sitematched skin samples from other individuals (Fig. 5d ). Importantly, p53 expression was also downregulated, with no increase of CDKN1A (Fig. 5d ). Similar downmodulation of CSL and p53 was found by immunofluorescence and LCM analysis of stromal cells of invasive SCCs versus an external set of normal skin samples, with CDKN1A levels also being decreased ( Fig. 5e and Supplementary Fig. 5k ).
To compare gene expression levels in affected versus unaffected stroma of the same individuals, we analysed discarded normal skin produced by closing of surgical excisions around SCCs, utilizing conditions for LCM/RT-qPCR analysis of formalin-fixed paraffin sections. Levels of CSL, p53 and CDKN1A expression were all significantly decreased in lesion-adjacent stroma versus distant unaffected skin from three different patients, confirming our other results (Fig. 5f ).
For LCM, captured stromal regions were well separated from localized nests of inflammatory cells, identified by immunohistochemistry with anti-CD45 antibodies. Significant leukocyte and endothelial cell contamination was further ruled out by RT-qPCR analysis with corresponding markers (CD45 and CD31) ( Supplementary Fig. 5h ). In addition, for in situ SCC stromal cells and matching controls, antibodies against the fibroblast marker PDGFRα were used for labelling of cells before capturing ( Supplementary Fig. 5j ).
Findings were further validated in a mouse model of mesenchymal CSL deletion, by examining skin lesions of mice at 3 months of age. Paralleling increase of proliferating fibroblasts (as shown in Fig. 1c ), LCM and RT-qPCR analysis showed concomitant downmodulation of p53 and CDKN1A expression and inverse upregulation of tenascin C in lesion-adjacent stroma relative to distant unaffected skin (Fig. 5g ). CD45 levels were slightly increased in some lesion stromal samples but not others ( Supplementary Fig. 5i ).
Consistent with the above results, skin-derived CAFs analysed for CSL expression ( Fig. 2a ) also showed low p53 levels (Fig. 6a ). On culturing, p53 remained poorly expressed in some CAF strains, whereas in others it reverted to higher levels. This suggested that the observed decrease of stromal p53 gene expression in fully established CAFs may result-at least in part-from paracrine influence of transformed keratinocytes or infiltrating inflammatory cells. A set of growth factors/cytokines known to be produced by these cells was tested for effects on stromal fibroblasts. Out of 14 factors, FGF-2 was capable of significantly downmodulating p53 expression in two different strains of HDFs, whereas others, such as CTGF, HGF and, to a lesser extent, PF4 and IL-6, exerted similar effects on only one strain (Fig. 6b,c and Supplementary Fig. 6a ).
Mirroring these results, treatment of two different HDF strains with ponatinib, a tyrosine kinase inhibitor in clinical trials for malignancies with increased FGFR signalling, as well as BGJ398, a more selective FGFR inhibitor 30 , caused upregulation of p53 expression and activity and associated cellular senescence (Fig. 6d,e and Supplementary  Fig. 6b-d) . Treatment with imatinib, another tyrosine kinase inhibitor with different spectrum of specificity and clinical use, exerted no such effect. Similar results were observed on treatment of CAF strains with the inhibitors, paving the way for further studies on their possible mechanism of action and use (Fig. 6f,g and Supplementary Fig. 6e ).
Stromal and cancer cell expansion results from compromised CSL and p53 function
To assess whether p53 suppression is sufficient to counteract the senescence program induced by downmodulation of CSL expression, HDFs were infected with shRNA lentiviruses against these genes, individually and in combination. As an alternative approach, the p53 gene was disrupted by infection with an anti-p53 CRISPR lentivirus ( Supplementary Fig. 7a ). p53 gene silencing or disruption overcame reduced proliferation and senescence caused by CSL downmodulation in parallel with suppression of CDKN1A and miR-34a expression ( Fig. 7a-d and Supplementary Fig. 7b ). Similar counteracting effects were exerted by CDKN1A knockdown ( Supplementary Fig. 7d,e ).
Interestingly, concomitant silencing of CSL and p53 resulted in overinduction of CAF marker genes such as PTSG2 (Cox-2), with a critical role in inflammation 17 , and POSTN (periostin), encoding a cancer-associated stromal matrix protein of importance for recruitment of macrophages to tumours 31 (Fig. 7e and Supplementary  Fig. 7c ). Upregulation of these genes was also found in HDFs with CSL and CDKN1A knockdown ( Supplementary Fig. 7f ). Expression of AP-1 family members was also enhanced in cells with concomitant CSL and p53 gene silencing (Fig. 7f) .
For in vivo testing, we developed an assay for cancer/stromal cell expansion, on the basis of injections of fluorescently labelled stromal and cancer cells into mouse ears followed by in vivo imaging. We monitored expansion of skin SCC-derived cells (SCC13) admixed with HDFs with knockdown of CSL, p53 or both. Cancer cell expansion was significantly enhanced by HDFs with dual silencing of CSL and p53 when compared with CSL or p53 alone (Fig. 8a-c and Supplementary  Fig. 8a ). Stromal cells themselves missing both CSL and p53 expanded to a much greater extent than those with silencing of CSL alone (Fig. 8a-c and Supplementary Fig. 8a) .
Histological analysis at the end showed SA-β-Gal positive stromal cells in lesions formed by SCC13 cells admixed with HDFs with single CSL knockdown, but not in those with HDFs with combined CSL and p53 knockdown (Fig. 8d ). Immunohistochemical analysis showed that lesions formed with HDFs lacking both CSL and p53 had higher levels of CAF markers (α-SMA, MMP1, tenascin C), enhanced leukocyte and macrophage infiltration (CD45 and F4/80) and angiogenesis (CD31) ( Fig. 8d and Supplementary Fig. 8b) .
Similar in vivo assays were repeated with HDFs with CSL plus/minus p53 silencing admixed with head/neck SCC Cal27 cells. Even in this case, HDFs with concomitant CSL and p53 silencing caused greater cancer cell expansion than HDFs with silencing of CSL only ( Supplementary Fig. 8c ). This resulted, by the end of the experiment, in neoplastic lesions with higher numbers of proliferating cancer and stromal cells ( Supplementary Fig. 8d,e ).
DISCUSSION
The stromal microenvironment can play a major role in tumour initiation and progression 1, 8, 9, [11] [12] [13] [14] . Together with, or even preceding, chronic inflammation and angiogenesis are alterations of stromal fibroblasts leading to CAF activation 32, 33 . Our findings indicate that at least two events are involved in transition from normal fibroblasts to CAFs: the first is downmodulation of CSL expression and/or function, with cellular senescence as a failsafe mechanism; this is followed by suppression of p53 expression and activity, with unimpeded cell expansion. Paracrine influences are probably involved in the second step (Fig. 8e) . These events do not necessarily occur sequentially, as there is substantial heterogeneity of cells, with downmodulation of p53 possibly preceding or concomitant with compromised CSL function.
Fibroblast senescence is coupled to acquisition of CAF-effector functions 5, 7 . Our evidence points to CSL as the underlying link, as this protein binds directly to many senescence-and CAF-determinant genes, suppressing their expression. Environmental insults, such as ultraviolet irradiation and smoking, are causes of stromal cell senescence/tissue atrophy and field cancerization, a major clinical condition that can be modelled in mice by mesenchymal deletion of the CSL gene 34 . In ongoing work, we have found that CSL expression is inhibited in dermal fibroblasts by both ultraviolet A irradiation and smoke extract exposure through mechanisms under investigation at present. Although ultraviolet A irradiation is a main cause of skin cancer 34 , smoke products can diffuse from surface epithelia and induce stromal cell senescence and increase cancer risk in multiple internal organs 35 . Differential CSL binding to target genes is an important determinant of its cell-type-specific regulatory functions 36, 37 . Genes to which CSL binds with high affinity are induced when CSL levels decrease, with similar effects resulting from Notch activation, converting CSL from a transcriptional repressor into an activator 36, 37 . Consistent with this mode of action, CSL silencing induced senescence-and CAF-effector genes in fibroblasts from various body sites but not in keratinocytes ( Supplementary Fig. 2j ), and similar upregulation resulted from increased Notch activity, such as could be induced in vivo by neighbouring ligand-expressing cells 26 .
Notch and p53 pathways interact at multiple levels, in a contextdependent manner 38 . Of particular importance, we uncovered that CSL and p53 proteins physically bind, with affinity comparable to that for other proteins with which they pair [39] [40] [41] . CSL suppresses p53 association with p300, a critical determinant of its activity 29 . More detailed molecular events are under investigation. Here, we focused on the functional significance of the findings. p53 can be involved in paracrine control of cancer development 42 and cancerassociated stromal changes 11, 43 . Consistent with this possibility, loss of p53 not only blocked senescence caused by CSL suppression but enhanced CAF marker expression. Underlying mechanisms include upregulation of CDKN1A, which can control transcription independently of the cell cycle [44] [45] [46] , and p53-induced disruption of AP-1 association with basal transcription apparatus 47 .
Reports of genetic mutations of p53 in CAFs were questioned by later studies 12 . An important form of p53 regulation is at the level of gene transcription [48] [49] [50] [51] [52] [53] . In contrast to less advanced AK lesions, p53 gene expression is downregulated in stromal fibroblasts of invasive and in situ skin SCCs, with paracrine influences of other cells as the probable culprit. FGF-2 caused consistent downmodulation of p53 expression in HDFs, with more limited effects exerted by CTGF and HGF. The findings are consistent with previous reports of negative control of p53 gene transcription by ERK/AP-1 activation 50,54,55 , and point to a possible, more selective mode of regulation connected with FGFR signalling. As well as activating mutations of FGFR1, FGFR2 or FGFR3 genes, upregulation of FGF ligands occurs frequently in several cancer types 56 . These factors can also be upregulated in CAFs themselves 17 , with a possible autocrine mechanism reinforcing p53 downmodulation in these cells. FGFR inhibitory compounds are in clinical trials at present 30 , and, as well as cancer cells, our findings suggest that they may also impact surrounding fibroblasts. By this or other approaches, restoration of CSL and p53 activity in these cells may serve to counteract the cancer-stroma co-evolution process.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper mediated gene silencing, RT-qPCR and ChIP were as previously reported 17, 58, 59 . For derivation of CAFs, surgically excised discarded skin SCC samples were cut into 1-2 mm pieces after removal of fat excess, followed by incubation in 2 ml of PBS containing 0.25 mg ml −1 of Liberase TL (Roche) for 40 min at 37 • C with gentle shaking. After equal volume addition of fetal bovine serum to stop the enzymatic digestion, the dissociated tissue was passed through a 10 ml syringe attached to a 70 µm sieve. Cells from the flowthrough were centrifuged, washed three times with DMEM 10% fetal bovine serum and seeded in a 10 cm tissue culture dish. Adherent cells were expanded for characterization as with HDFs. Skin SCC13 (ref. 60 ) and oral Cal27 SCC cells 61 were originally reported and subsequently checked for the presence of oncogenic mutations 62 (https://cansar.icr.ac.uk/cansar/ cell-lines/CAL-27/mutations). They have been routinely tested for mycoplasma and have not been authenticated for short tandem repeat profiling. They were infected with a DsRed2-expressing lentivirus and puromycin selected. Human THP-1 monocytic leukaemic cells were differentiated into adherent macrophages (M ) by treatment with 10 µM 12-O-tetra-decanoylphorbol-13-acetate plus/minus activation by overnight treatment with 1 µg ml −1 lipopolysaccharide. Human umbilical vein endothelial cells (HUVECs) and mouse primary lung endothelial cells were provided by T. Petrova (University of Lausanne, Switzerland). The human WI-38 diploid lung fibroblast cell line was purchased from the American Type Culture Collection. None of the used human cell lines is listed in the NCBI Biosample Database of misidentified cell lines.
HDFs were infected with lenti-and retroviruses at high titre, sufficient to infect the vast majority of HDFs so that similar results were obtained in experiments with and without antibiotic resistance selection: results in Fig. 7a ,e,f and Supplementary Fig. 7b,c,d were obtained without selection, elsewhere with selection. The list of shRNA vectors, siRNAs, primers and antibodies is provided in Supplementary Table 3 . Transient transfection and promoter activity assays were also as described 57 using the pG13-p53 Luc plasmid as reporter 63 .
CAF strains stably infected with a doxycycline-inducible lentiviral vector for Myc-tagged CSL in parallel with empty vector control were treated for 5 days with doxycycline (500 ng ml −1 ) before RT-qPCR and immunoblot analysis. For in vivo assays, CAFs (strain no. 2) were infected with a lentiviral vector for constitutive CSL expression in parallel with empty vector control, followed, 7 days after infection, by injection into mice with admixed DsRed-expressing SCC13 cells.
For disruption of the p53 gene, the 20-nucleotide CRISPR RNA sequence (5 -ACTTCCTGAAAACAACGTTC-3 ) targeting the end of exon 2 of the human TP53 gene, was selected as guide RNA (sgRNA) from the published genome-scale sgRNA library on the basis of being close to the beginning of the coding region and predicted minimal off-target probability 64 . The corresponding oligonucleotide was cloned into the lentiCRISPR vector followed by lentivirus production in 293T as previously described 64 . HDFs were infected with the resulting virus, followed, 24 h after infection, by selection for the virally transduced puromycin resistance gene. 7 days after selection, stably transduced cells (approximately 1,000 cells, that is, 5% of the originally infected cells) were pooled and expanded before further analysis in comparison with parental HDFs. The same lentiCRISPR vector was used to target p53 in two other HDF strains with similar efficacy.
Treatment of HDFs with jagged 1 ligand was as previously reported 57 , using rabbit anti-human IgG (Sigma l2011) plus/minus rhJagged1 Fc chimaera (R&D systems; 1277-JG) for coating of dishes. HDFs were treated with the following growth factors/cytokines at the indicated concentrations every 24 h for 3 days: SHH at 2 µg ml −1 , CTGF at 200 ng ml −1 , HGF, FGF-2, activin A, PF4 (also known as CXCL4), IL-6, MCP1 (also known as CCL2), IL-10 and SDF1 (also known as CXCL12) at 100 ng ml −1 , PDGF-BB at 50 ng ml −1 , IL-4 at 25 ng ml −1 , IL-1 β and TGF-β3 at 10 ng ml −1 final concentration.
Plasmid constructs. The plasmid encoding for the inducible activated form of Notch1 (pIND-NICD) has been previously described 59 . To make doxycyclineinducible Myc-tagged RBPJk plasmid, a PCR product using gateway primers from pcDNA-RBPJk (ref. 65 ) was cloned into the pENTR-D-TOPO entry vector (Life Technologies) and transferred through the Gateway LR Clonase system (Life Technologies) into the pINDUCER20 destination vector. RBPJk-Myc was further subcloned into pMX-neo using BamHI and SalI cuts for the PCR product and BamHI and XhoI cuts for the plasmid.
Cell assays. Clonogenicity, Alamar Blue and SA-β-Gal activity assays, using a commercially available chromogenic assay kit (Cell Signaling), were as reported 62 .
For senescence, second passage mouse dermal fibroblasts were processed for SA-β-Gal staining 3 days after plating (5×10 3 cells/60 mm dish), whereas human fibroblasts were assayed 9 days after shRNA-mediated gene silencing. β-Gal activity assays at optimal pH (pH 4) were carried out as a control for β-galactosidase activity. Cells were counterstained with Nuclear Fast Red and a minimum of 100 cells from at least four different fields per condition were counted, using images acquired digitally with a Leica DM2000 microscope.
For clonogenicity assays, second passage mouse dermal fibroblasts plus/minus CSL gene deletion and human fibroblasts plus/minus shRNA-mediated silencing of CSL, individually or together with p53, were plated at clonal density in triplicate dishes (10 3 cells/60 mm dish) and cultivated for 2 weeks, followed by colony quantification.
For proliferation, human fibroblasts plus/minus CSL silencing were tested, 9 days after infection, by a 4 h incorporation assay with 5-bromo-2 -deoxyuridine (BrdU; Amersham), followed by immunofluorescence analysis with anti-BrdU antibody (BD Biosciences) according to the manufacturer's instructions. The percentage of BrdU-positive cells was evaluated in triplicate wells by digitally captured images and ImageJ software analysis, using DAPI staining for total cell identification. For Alamar Blue fluorescence intensity assays, HDFs were plated, 2 days after shRNAmediated CSL silencing, onto 96-well plates (1,000 cells/well; triplicate wells per condition) followed by fluorescence intensity determination with a fluorimeter (Molecular Devices).
For gene expression, human fibroblasts were collected for RT-qPCR analysis 9 days after shRNA CSL gene silencing and 3 days after siRNA transfection. RNA samples were analysed in triplicate with gene-specific primers and 36β4 for normalization.
For p53 activity assays, HDFs were co-transfected in triplicate dishes with a p53 luciferase reporter plasmid (PG13-luc; 3 µg/well) and two siRNAs against CSL versus scrambled controls. 293T cells were transfected in triplicate wells with the same p53 reporter (PG13-luc; 3 µg/well) plus/minus a p53-expressing vector (2 µg/well) and increasing amounts of a CSL-expressing plasmid (0.25, 0.5, 1, 2 µg). In all cases, luciferase activity was determined 48 h later, using total protein amount for normalization. Tissue analysis. SA-β-Gal activity assays of tissue sections were carried out using a commercially available chromogenic assay kit (Cell Signaling) as for cultured cells.
LCM, using an Arcturus XT microdissection system (Applied Biosystems), and ensuing RNA preparation and analysis, were carried out as before 17, 66, 67 ; for RNA purification from paraffin sections an RNeasy FFPE Kit (Qiagen) was used. For immunofluorescence-guided LCM, frozen blocks of normal skin and in situ SCCs were freshly cut and immediately fixed with 75% ethanol for 30 s. After a brief blocking procedure (in 10% donkey serum in nuclease-free PBS for 2 min), sections were incubated with a mixture of fluorescein isothiocyanate (FITC)-conjugated antibodies against PDGFRα and propidium iodide for 2 min, followed by quick rinsing with PBS. The air-dried sections were then used for fluorescence-guided LCM using an Arcturus XT microdissection system as before. RNA samples were analysed in triplicate with gene-specific primers and β-actin for normalization, except for paraffin samples, in which 36β4 was used for normalization.
Intradermal ear injection and in vivo imaging. Mouse ear injections of cells
were carried out in 10-week-old male NOD/SCID mice with interleukin-2 receptor gamma chain null mutation (Il2rg−/−), with only slight modifications of a recently described procedure 68 . SCC13 cells (1 × 10 5 ) expressing the DsRed2 fluorescence marker were admixed with equal numbers of GFP-expressing HDFs with shRNAmediated silencing of CSL or p53, individually or in combination. Alternatively, for the in vivo experiment of Supplementary Fig. 8c -e, DsRed2-expressing oral Cal27 SCC cells were admixed with HDFs labelled with the PHK67 green fluorescent cell membrane dye (Sigma-Aldrich), according to the manufacturer's instructions (4 × 10 −6 M of dye for 1 × 10 6 cells). In all cases, cells were concentrated by centrifugation and resuspended in 3 µl of sterile Hanks' balanced salt solution per ear injection using a 33-gauge microsyringe (Hamilton). Live images were taken every 2-3 days with a fluorescence stereomicroscope (Leica M205F) starting 24 h post-injection. Quantification of red (DsRed2-SCC) and green (GFP-HDF) fluorescence DOI: 10.1038/ncb3228 intensity values (intensity × surface area) was achieved by ImageJ software analysis of digitally acquired images using the Lasso Toll to focus on the regions of interest. Mice were sacrificed 3 weeks after injection for direct tissue analysis.
Immunodetection techniques. Conditions for immunoblotting, immunofluorescence and immunohistochemistry were as described previously 17, 66 . Antibodies are listed in Supplementary Table 4 (including further information for the validation profile from the 1DegreeBio website).
Affinity-purified anti-CSL polyclonal antibody was made in rabbit (Eurogentec) by immunization against two epitopes, one from the BTD region of CSL (amino acids 209-224: LDDDESEGEEFTVRDG) and the other from the CTD region (amino acids 426-440: FTYTPEPGPRPHCSA), both sequences being conserved in all seven CSL isoforms. After serum heat inactivation, antibodies were affinity purified on Sepharose columns (activated CH Sepharose 4B, GE Healthcare) coupled with the immunizing peptides. Fractions were eluted with pH 2.5 glycine into Tris buffer solution for pH neutralization. Protein eluted fractions (as determined by Bradford) were pooled and concentrated by ultrafiltration to 2 mg ml −1 in PBS (Amicon Ultra-15 30KD, Millipore). Validation of antibody specificity was assessed by IP-western blot analysis of cells ± overexpression of Myc-tagged CSL, and immunostaining using neutralizing peptide for signal neutralization.
Immunofluorescence images were acquired with a Zeiss LSM700 Meta laserscanning microscope. For quantification of immunofluorescence nuclear signal, digitally acquired images for each colour channel were separately imported into ImageJ software and converted into binary images. For single-cell quantification of signal, the numbers of pixels (representing the intensity of the fluorescence signal) were measured using the function 'Measurement' for multiple regions of interest on previously selected nuclei, on the basis of DAPI staining. For singlecell CSL signalling measurements on tissue sections, only vimentin-positive and CD68-negative cells were taken into account. For cytoplasmic signal quantification, fluorescence intensity was measured in the acquired fields and normalized to number of cells. All measurements were exported as Excel Microsoft files.
Co-immunoprecipitation experiments. Cells were lysed in NP-40 buffer, and 500 µg total protein extracts were incubated overnight at 4 • C with 10 µg primary antibodies against the CSL (home made; affinity purified) and p53 (DO1) proteins or the Myc-epitope tag (Zymed) in parallel with corresponding non-immune IgGs. This was followed by addition of packed protein A/G magnetic beads (25 µl per sample; Novex) and further incubation for 4 h at 4 • C. Beads were washed five times with NP-40 buffer, eluted in 60 µl ×2 SDS sample buffer at 95 • C for 5 min and analysed by gel electrophoresis and immunoblotting.
For purified proteins, 100 ng of recombinant CSL/RBP-Jκ and p53 proteins, purchased from Origene (RBPJ transcript variant 1; p53 transcript variant 1) were incubated with each other in equal amounts for 20 min at room temperature in Trisbuffered saline and 0.05% Tween, followed by standard co-immunoprecipitation assays as above.
For p300 association, 293T cells were co-transfected with a p53-(3 µg) and a CSL-expressing plasmid in increasing amounts (0, 1.5, 3 µg; in 10 cm dishes), followed, 24 h later, by immunoprecipitation of p300 and immunoblotting as before.
Microscale thermophoresis. Purified recombinant p53, labelled with a RED-NHS protein labelling kit (NanoTemper), was incubated at a constant concentration (900 nM) with twofold serial dilutions of CSL (from 9 µM to 0.75 nM) in standard MST buffer. Equal volumes of proteins were mixed by pipetting and incubated for 20 min at room temperature. Mixtures were enclosed in standard-treated glass capillaries and loaded into the instrument (Monolith NT.115, NanoTemper). Measurement protocol times were as follows: fluorescence before 5 s, MST on 30 s, fluorescence after 5 s, delay 25 s. Both light-emitting diode power and laser power were kept at 50%. K d values were determined with the NanoTemper analysis tool.
DNA-oligo pulldown assay. A double-stranded oligonucleotide corresponding to
the CDKN1A promoter region with wild-type CSL and p53 recognition sequences, and one with two nucleotide substitutions disrupting such sequences (as shown in Supplementary Table 3 ), were commercially obtained (Miltenyi) in biotinylated form. 300 µg of total protein extracts from 293T cells (obtained by a freeze-thawing method) were incubated with 1 µg oligonucleotides for 20 min at room temperature in 500 µl binding buffer containing 12 mM HEPES (pH 7.9), 4 mM Tris (pH 7.9), 150 mM KCl, 1 mM EDTA, 12% glycerol, 1 mM dithiothreitol and 10 µg poly(dI-dC) competitor. This was followed by addition of 30 µl streptavidin-magnetic beads (Pierce), which had been pre-treated in 500 µl binding buffer with 1 mg ml −1 BSA, 50 µg poly(dI-dC) and 50 µg of sheared salmon sperm DNA for 30 min at room temperature. After 2 h of incubation at 4 • C, beads were washed three times with binding buffer and the protein-DNA complexes were eluted with 30 µl ×2 SDS sample buffer at 95 • C for 5 min, followed by gel electrophoresis and immunoblotting analysis of the recovered material.
Transcriptome analysis. HDFs were infected with two different siRNAs against CSL in parallel with a control virus. Total RNA was extracted 3 days post-transfection using the directZol RNA miniprep kit (Zymo Research) with on-column DNase treatment. RNA quality was verified on the bioanalyzer (Agilent) with RIN > 8. Four micrograms of total RNA was used for library preparation using a Truseq kit (Illumina). A single read was done on the Illumina HiSeq 2000 sequencer at the Genomic Technologies Facility (Lausanne University). Reads have been trimmed using Trimmomatic (v0.22) and then mapped to the human hg19 reference genome using TopHat (v2.0.8b). Gene expression levels have been evaluated using the HTSeq package (release 0.5.4p1). Data can be retrieved from GEO no. GSE65473.
Published gene expression profiles of CAFs from skin SCCs (derived from five patients of the general population (cSCC) and from four patients with recessive dystrophic epidermolysis bullosa (RDEB-SCC) in comparison with dermal fibroblasts from three healthy individuals; GSE37738), head and neck SCCs (derived from seven patients and compared with oral mucosa fibroblasts from five healthy individuals, GSE38517), breast cancer (derived from 23 patients and compared with breast fibroblasts from five healthy individuals, GSE29270) and lung cancer (derived from four patients with non-small-cell lung cancer in comparison with lung fibroblasts from 15 unaffected individuals GSE22862), were analysed for normalized expression levels of CSL. Results were expressed as log intensity or log ratio values depending on the microarray platform.
For comparative transcriptomic analysis, gene expression profiles in skin and head/neck SCC CAFs versus normal fibroblasts, one single-colour Agilent data set (GEO GSE37738, for skin CAFs) and one Affymetrix data set (GEO GSE38517, for oral CAFs) were used. Agilent data were background subtracted (normexp method) and normalized with the quantile function, whereas Affymetrix data were processed with the RMA algorithm. Log 2 ratios of the individual tumours versus mean values of control tissues were calculated separately for each data set. Boxplots were created with R v2.13, using normalized expression values of CSL in skin (GSE37738), head/neck (GSE38517), lung (GSE22862) and breast (GSE29270) CAFs versus corresponding normal fibroblasts. Pathways or processes with a statistically significant distribution (P < 0.05) among the concordantly and discordantly regulated groups of genes as identified by Metacore and Gene Ontology gene family classification are provided in Supplementary Table 1 .
ChIP and ChIP-Seq. ChIP assays with antibodies against CSL or p53 versus non-immune IgG control were carried out as previously described 58 followed by determination of binding enrichment for the indicated sites; primer sequences and antibodies are given in Supplementary Tables 3 and 4, respectively. For ChIP-Seq analysis, immunoprecipitated DNA from HDFs was processed as for ChIP assays 58 , using 5 µg of home-made and 10 µl of commercially available (Cell Signaling) antibodies against CSL per 10 6 cells. The ChIPed DNA was quantified by fluorometry on a Qubit system (Invitrogen). A total of 10 ng of DNA was used for library preparation using a NEBNext ChIP-Seq Library Prep reagent set from Illumina, as recommended by the manufacturer. Burrows-Wheeler Aligner (http://bio-bwa.sourceforge.net) was used for FASTQ file alignments and, for peak detection, MACS software (http://liulab.dfci.harvard.edu/MACS) with default parameters. The Integrative Genomics Viewer (IGV) (http://www.broadinstitute. org/igv) was used for graphic illustration of ChIP-Seq peaks, and ENCODE data (http://genome.ucsc.edu/ENCODE) for information on chromatin organization. ChIP-Seq data are deposited in the public repository (GSE59942).
Statistical analysis.
Data are presented as mean ± s.d., mean ± s.e.m. or ratio among experimental groups and controls as indicated in the figure legends. For gene expression and functional testing assays, statistical significance of differences between experimental groups and controls was assessed by one-/two-tailed unpaired or paired t-test and one-/two-sided one-sample t-test as indicated in the figure legends, except for Fig. 5c , where a Pearson correlation test was carried out. * P < 0.05 was considered as statistically significant, unless otherwise indicated.
For comparative transcriptomic analysis, two-class comparison analysis was carried out using the moderated t-statistic available within the limma package 69 . Linear models and empirical Bayes methods were used for assessing differential expression in microarray experiments. Gene Ontology enrichment analysis was carried out with the Fisher exact test, using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7. Data meet the assumptions of the tests used; variation within each group of data has not been estimated.
For ear injection/tumorigenicity assays, a sample size of adequate statistical power was ensured by minimizing the individual animal variability issue through parallel ear injections of the same animals with control versus experimental combinations of cells. No statistical method was used to predetermine sample size.
No exclusion criteria were adopted for animal studies and sample collection, except for RT-qPCR analysis in the case of undetectable amplification signal.
No randomization was used and the researchers involved in the study were not blinded during sample obtainment or data analysis. Supplementary Fig. 3e similar results were obtained with a second independent strain (as shown in Supplementary Figs 2b, 6a -c and 7b,c respectively); for Figs 1g and 3a results with two other independent strains are shown in Supplementary Figs 2b,c and 3f . Findings in Figs 1g,j and 7a,c and Supplementary  Fig. 3c were also validated by alternative approaches in Supplementary Figs 2d,e,h,  7b,d and 3e , respectively. For IP-western blot in Fig. 4b similar results were obtained with another HDF strain ( Supplementary Fig. 4a,b) ; for Fig. 4d ,i similar results were obtained, respectively, in one and two other independent experiments ( Supplementary Fig. 4d ).
Reproducibility of experiments. For RT-qPCR and
Luciferase reporter activity in Fig. 4g Supplementary Figure 2 CSL as negative regulator of dermal fibroblast senescence-and CAF-determinant genes. (a) HDFs infected with two shRNA lentiviruses against CSL were analyzed, 3 days later, for CSL expression by immunoblotting. Densitometric quantification showed reduction of CSL to 3% and 6% of control. Unprocessed original scans of blots are shown in Supplementary Fig. 9 . (b) SA-ß gal and clonogenicity assays of foreskin-derived HDFs (strain #4) plus/minus CSL silencing as shown in Fig. 1f , g for strain #1 adult-derived HDFs; for SA-β-Gal activity n=290 (shCtrl), 264 (shCSL1), 217 (shCSL2) cells assessed from 4, 9 and 11 fields, respectively; mean +/-s.d., two-tailed unpaired t-test, *p<0.05. (c) Clonogenicity assays of another adult-derived HDF strain (♯2) plus/minus CSL silencing; n=3 biological replicates/condition, two-tailed unpaired t-test, *p<0.05. (d) HDFs plus/minus CSL silencing were tested by 5-bromo-2`-deoxyuridine (BrdU) incorporation assay; n= 113(shCtrl), 97 (shCSL1), 108 (shCSL2) cells assessed from 8 fields, mean +/-s.d., two-sided one sample t-test, *p<0.0005. (e) Cells as in (d) were tested for Alamar blue fluorescence cell density assays; data are presented as fluorescence intensity change over day 1. (f and g) Two HDF strains (♯1 and ♯4) plus/minus CSL silencing by shRNAs (f) and siRNAs (g) examined for senescence-determinant genes in Fig. 1h ,i were analyzed by RT-qPCR for indicated CAF marker genes. (h) Immunofluorescence analysis of HDFs plus/minus CSL silencing by siRNAs for p21 WAF1/Cip1 and IL6, with DAPI staining for cell identification. Shown are representative images and quantification of fluorescence signal intensity by Image J software analysis. For p21 n=164 (siCtrl), 190 (siCSL1), 114 (siCSL2) cells, for p53 and IL6 n=222 (siCtrl), 194 (siCSL1), 97 (siCSL2) cells assessed from 4 fields. Whisker boxes: min to max, median center; two-tailed unpaired t-test, *p<0.05. (i) Early passage oral (HOF), breast (HBF), lung (HLF) fibroblasts and WI38 diploid lung fibroblast line plus/minus shRNA-mediated CSL silencing as in Fig. 1k ,l were tested by clonogenicity assays; for WI38 n=3 biological replicates/condition, mean +/-s.d., two-tailed unpaired t-test, *p<0.05. (j) Primary human keratinocytes plus/minus siRNA-mediated CSL silencing were analyzed, 3 days after transfection, by RT-qPCR for indicated genes. Figure 7 Abrogation of HDF senescence with enhancement of CAF marker expression by concomitant CSL and p53 silencing or gene disruption. (a) Early passage HDFs were infected with a CRISPR lentivirus against p53, followed by selection for the virally-transduced antibiotic resistance gene (puromycin). Resulting colonies (>500) were pooled and analyzed (CRISPR), in parallel with parental control cells (WT), for p53 protein levels by immuno-blotting, and for expression of p53 target genes (p21 WAF1/Cip1 , miR34-a, MDM2) by RT-qPCR (left and right panels, respectively). Similar results were obtained with two other strain of HDFs of independent origin. Unprocessed original scans of blots are shown in Supplementary Fig. 9 . (b) HDFs (a second strain besides that tested in Figure 7a ) were infected with control versus p53 silencing retroviruses, followed by infection with control versus CSL silencing lentiviruses. Number of cells positive for SA-ß-Gal activity was determined a week later (left panel); from left to right n (cells)=372, 223, 236, 332, 370, 373 assessed 
